<DOC>
	<DOC>NCT00820911</DOC>
	<brief_summary>This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.</brief_summary>
	<brief_title>Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criteria: Patient has been maintained on study drug for 12 months in the core study Exclusion criteria: Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney transplant</keyword>
	<keyword>AEB071</keyword>
</DOC>